<DOC>
	<DOCNO>NCT02420418</DOCNO>
	<brief_summary>Background : . Bipolar disorder tobacco use disorder top cause disability mortality worldwide Objective : The aim study evaluate N-acetyl-cysteine ( NAC ) adjunctive treatment patient bipolar .disorders tobacco use disorder ( TUD ) , determine whether NAC reduces alteration biomarkers inflammatory oxidative stress Methods : This study conduct double-blind , randomize , placebo controlles add NAC placebo .bipolar disorder tobacco use disorder Londrina State University , Brazil .</brief_summary>
	<brief_title>The Effect N- Acetylcysteine Inflammatory Oxidative Stress Biomarkers</brief_title>
	<detailed_description>Tobacco use disorder bipolar disorder top cause disability mortality worldwide . The aim study evaluate N-acetyl-cysteine ( NAC ) adjunctive treatment patient Tobacco use disorder comorbid bipolar disorder ( ( N=72 NAC/placebo ) recruit outpatient smoke cessation unit Londrina State University , Brazil . The design randomize , double-blind , placebo control clinical trial 12 week adjunctive treatment N-acetyl-cysteine ( NAC ) , 1800mg/day . Participants patient bipolar disorder without TUD , allocate one two group random receive NAC placebo For evaluation oxidative stress biomarkers assess among others malondialdehyde ( MDA ) , lipid hydroperoxide , nitric oxide metabolite ( NOx ) , antioxidant potential total plasma ( TRAP ) , advanced oxidation protein product ( AOPP ) , superoxide dismutase ( SOD ) , catalase , total glutathione ( GSH ) oxidize ( GSSG ) , paraoxonase ( PON 1 ) activity thiol group ( SH-group ) .For evaluation inflammation biomarkers analyze : BDNF , GM-CSF , IFN-γ , IL-1β , IL-10 , IL-12 ( p70 ) , IL-13 , IL-15 , IL-17 , IL-1RA , IL-2 , IL-2R , IL-4 , IL-5 , IL-6 , IL-6R , IL-7 , IL-8 , Leptin , TNF-α , TNF-RI , TNF-RII , high-sensitivity C-reactive protein ( hs-CRP ) , erythrocytes sedimentation rate ( ESR ) , homocysteine , haptoglobin , albumin , uric acid fibrinogen .</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>To include study participant must motivate smoker stop tobacco use Age great equal 18 less 65 year Both sex All race Capacity consent study carefully follow guideline procedure sign term free inform consent . Will include comorbid bipolar , depressive anxiety disorder tobacco use 20 cigarette per day , control group without mood disorder without tobacco use disorder . We exclude subject : abnormal blood value follow laboratory test : *hemogram , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , urea creatinine actual lifetime axisI diagnosis ( include schizophrenia , psychoorganic syndrome , delirium , dementia , amnestic , cognitive disorder ) medical illness , include HIV hepatitis B C , ( auto ) immune disorder immune modulatory drug , e.g . glucocorticoid use antioxidant . These situation affect inflammatory / immune process .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Tobacco use disorder bipolar disorder</keyword>
	<keyword>N-acetylcysteine</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>inflammation</keyword>
</DOC>